- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05419180
Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Recruiting
- Centre de Référence Epilepsies Rares / Centre Investigation Clinique (CIC) - Hôpital Necker-Enfants Malades
-
Principal Investigator:
- Rima NABBOUT, Pr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Retrospective part of the research:
The medical records of CRéER patients with the following criteria will be included in the retrospective part of the research by an investigator:
- With pharmacoresistant epilepsy, i.e. a history of failure of two well-conducted and well-tolerated antiepileptic treatment regimens, either as monotherapy or as combination therapy,
- Receiving or having received a treatment combining stiripentol and carbamazepine for a period of at least 15 days,
- Having at least one evaluation data after the initiation of treatment with stiripentol and carbamazepine (a follow-up visit after the initiation of the study treatment),
For which an information note indicating the possibility of opposing the processing of data has been provided.
- Prospective part of the research:
Among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research:
- Currently treated with stiripentol in combination with carbamazepine for at least 15 days and still being followed in the center,
- Weighing at least 5 kg (minimum weight in accordance with the blood volume taken),
- Having read, or whose parents have read, the information note and signed the consent form. For children, if their level of understanding allows it, their consent will also be sought,
- Having sufficient knowledge, or whose parents or legal guardians have sufficient knowledge, of the French language to read, understand and complete the research documents,
- Members or beneficiaries of a social security scheme. These patients, both children and adults, will be welcomed at the CIC.
Exclusion Criteria:
- Retrospective part of the research : Patients objecting to the collection of their data will not participate in the research.
- Prospective part of the research :
Patients with the following criteria will not be able to participate in the prospective part of the research:
- Participating simultaneously in another interventional clinical trial or in a period of exclusion following a previous trial,
- Whose state of health does not allow him to give his consent,
- Under guardianship or curatorship,
- Under judicial protection or person deprived of liberty.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: stiripentol
|
Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Age
Time Frame: through study completion, an average of 1 year
|
Age of onset, nature of the first seizure and description of the type of the first seizure.
|
through study completion, an average of 1 year
|
Previous antiepileptic treatments received
Time Frame: through study completion, an average of 1 year
|
proportion of patients having received each antiepileptic treatment; for the treatments received, description of the reasons for stopping.
|
through study completion, an average of 1 year
|
Surgery
Time Frame: through study completion, an average of 1 year
|
proportion of patients having undergone epilepsy surgery.
|
through study completion, an average of 1 year
|
Adjustment of carbamazepine treatment over the time
Time Frame: through study completion, an average of 1 year
|
mean and median duration of treatment, mean and median daily dose received, dose change(s) during treatment...
|
through study completion, an average of 1 year
|
Adjustment of stiripentol treatment over the time
Time Frame: through study completion, an average of 1 year
|
mean and median duration of treatment, mean and median daily dose received, dose change(s) during treatment...
|
through study completion, an average of 1 year
|
Adjustment of concomitant treatments over the time
Time Frame: through study completion, an average of 1 year
|
continuation without change, change in dosage, discontinuation
|
through study completion, an average of 1 year
|
monthly seizures over the time
Time Frame: through study completion, an average of 1 year
|
description of the average number of monthly seizures since the last visit (total and by type of seizure)
|
through study completion, an average of 1 year
|
status epilepticus in the past
Time Frame: through study completion, an average of 1 year
|
proportion of patients who presented with status epilepticus
|
through study completion, an average of 1 year
|
duration of the status epileticus over the time
Time Frame: through study completion, an average of 1 year
|
duration of status epilepticus
|
through study completion, an average of 1 year
|
emergency room consultation and/or hospitalization over the time
Time Frame: through study completion, an average of 1 year
|
Proportion of patients requiring an emergency room consultation and/or hospitalized during the period preceding the visit.
|
through study completion, an average of 1 year
|
emergency antiepileptic treatment over the time
Time Frame: through study completion, an average of 1 year
|
Proportion of patients taking emergency antiepileptic treatment in the period before each visit
|
through study completion, an average of 1 year
|
frequency of the status epileticus over the time
Time Frame: through study completion, an average of 1 year
|
frequency of status epilepticus
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention rate of the combination
Time Frame: through study completion, an average of 1 year
|
The retention rate of the combination will correspond to the proportion of patients still receiving the combination (carbamazepine and stiripentol) at a given time.
|
through study completion, an average of 1 year
|
Response to the combination
Time Frame: through study completion, an average of 1 year
|
The rate of patients responding to the combination will be defined by the percentage of patients in whom a 50% reduction in visible seizures will be observed since the initiation of the carbamazepine and stiripentol combination. Will be estimated: oThe percentage of responder patients at the post-initiation visit of the combination (first follow-up visit after initiation of stiripentol) oThe percentage of responder patients during treatment regardless of the duration of treatment after which the response is obtained. oThe cumulative incidence of responder patients. |
through study completion, an average of 1 year
|
Tolerance of the combination.
Time Frame: through study completion, an average of 1 year
|
Proportion of patients with Adverse Effects (AEs) related to the combination or to one of the treatments,
|
through study completion, an average of 1 year
|
Frequency and nature of the adverse events over the time
Time Frame: through study completion, an average of 1 year
|
Frequency and nature of the adverse events over the time
|
through study completion, an average of 1 year
|
Abnormal biological parameters (NFS and liver)
Time Frame: through study completion, an average of 1 year
|
proportion of patients with abnormal laboratory values (NFS and liver function) during
|
through study completion, an average of 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Concentration (Cmax) for stiripentol, carbamazepines and its metabolites
Time Frame: through study completion, an average of 1 year
|
Cmax calculation
|
through study completion, an average of 1 year
|
Area under the plasma concentration versus time curve (AUC) 0-8 for stiripentol, carbamazepines and its metabolites
Time Frame: through study completion, an average of 1 year
|
AUC0-8 calculation
|
through study completion, an average of 1 year
|
Area under the plasma concentration versus time curve (AUC) 0-24 for stiripentol, carbamazepines and its metabolites
Time Frame: through study completion, an average of 1 year
|
AUC0-24 calculation
|
through study completion, an average of 1 year
|
Time of Maximum (Tmax)concentration for stiripentol, carbamazepines and its metabolites
Time Frame: through study completion, an average of 1 year
|
Tmax calculation
|
through study completion, an average of 1 year
|
half-life (t1/2) for stiripentol, carbamazepines and its metabolites
Time Frame: through study completion, an average of 1 year
|
t1/2 calculation
|
through study completion, an average of 1 year
|
Pre-dose trough concentration (Ctrough) for stiripentol, carbamazepines and its metabolites
Time Frame: through study completion, an average of 1 year
|
Ctrough calculation
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CARBASTIR (STP225)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacoresistant Focal Epilepsies
-
Assistance Publique - Hôpitaux de ParisMedtronicRecruitingEpilepsy | Focal Epilepsy | Drug Resistant | Drug-resistant Focal Epilepsy | Epilepsies, FocalFrance
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingDrug Resistant Epilepsy | Pediatrics | Epilepsies, FocalFrance
-
King's College LondonKing's College Hospital NHS TrustCompleted
-
Peking Union Medical College HospitalGuidon Pharmaceutics Ltd.RecruitingRefractory Focal EpilepsyChina
-
UCB Biopharma S.P.R.L.PRA Health SciencesCompletedHighly Drug-resistant Focal EpilepsyBelgium, Bulgaria, Germany, Hungary, Netherlands, Spain
-
UCB Biopharma SRLTerminatedAn Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal EpilepsyHighly Drug-resistant Focal EpilepsyBelgium, Bulgaria, Germany, Hungary, Netherlands, Spain
-
InSightecFood and Drug Administration (FDA)Recruiting
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); MedtronicActive, not recruitingEpilepsyUnited States
-
Seoul National University HospitalDongsan Medical Center; Konkuk UniversityCompleted
-
Hospices Civils de LyonUnknown
Clinical Trials on Stiripentol
-
BiocodexCompletedPrimary HyperoxaluriaFrance
-
BiocodexNot yet recruitingChronic Renal InsufficiencyBulgaria
-
Cook Children's Health Care SystemNo longer availableDravet Syndrome | Epileptic Encephalopathies Associated With SCN1A MutationsUnited States
-
BiocodexCompleted
-
University of Colorado, DenverNo longer available
-
Children's Hospital Medical Center, CincinnatiApproved for marketingDravet SyndromeUnited States
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
University College, LondonThe Leeds Teaching Hospitals NHS Trust; Cambridge University Hospitals NHS... and other collaboratorsUnknown